These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23726887)

  • 1. Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation.
    Valencia-Serna J; Gul-Uludağ H; Mahdipoor P; Jiang X; Uludağ H
    J Control Release; 2013 Dec; 172(2):495-503. PubMed ID: 23726887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers.
    Valencia-Serna J; Kucharski C; Chen M; Kc R; Jiang X; Brandwein J; Uludağ H
    J Control Release; 2019 Sep; 310():141-154. PubMed ID: 31430499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells.
    Arthanari Y; Pluen A; Rajendran R; Aojula H; Demonacos C
    J Control Release; 2010 Aug; 145(3):272-80. PubMed ID: 20403398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
    Valencia-Serna J; Aliabadi HM; Manfrin A; Mohseni M; Jiang X; Uludag H
    Eur J Pharm Biopharm; 2018 Sep; 130():66-70. PubMed ID: 29913272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of water-insoluble hydrophobic polyethylenimines as RNAi vehicles in chronic myeloid leukemia therapy.
    Ansari AS; K C R; Jiang X; Uludaǧ H
    J Biomed Mater Res A; 2021 Nov; 109(11):2306-2321. PubMed ID: 33964112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesterol grafted cationic lipopolymers: Potential siRNA carriers for selective chronic myeloid leukemia therapy.
    Remant KC; Thapa B; Valencia-Serna J; Domun SS; Dimitroff C; Jiang X; Uludağ H
    J Biomed Mater Res A; 2020 Mar; 108(3):565-580. PubMed ID: 31714657
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Kc R; Thapa B; Ubeda A; Jiang X; Uludağ H
    Stem Cells Dev; 2019 Jun; 28(11):734-744. PubMed ID: 30585758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
    Koldehoff M; Zakrzewski JL; Beelen DW; Elmaagacli AH
    Cancer Gene Ther; 2013 Jul; 20(7):421-7. PubMed ID: 23788109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
    Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells.
    Withey JM; Marley SB; Kaeda J; Harvey AJ; Crompton MR; Gordon MY
    Br J Haematol; 2005 May; 129(3):377-80. PubMed ID: 15842662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodegradable charged polyester-based vectors (BCPVs) as an efficient non-viral transfection nanoagent for gene knockdown of the BCR-ABL hybrid oncogene in a human chronic myeloid leukemia cell line.
    Yang C; Panwar N; Wang Y; Zhang B; Liu M; Toh H; Yoon HS; Tjin SC; Chong PH; Law WC; Chen CK; Yong KT
    Nanoscale; 2016 Apr; 8(17):9405-16. PubMed ID: 27092903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcr-abl silencing by specific small-interference RNA expression vector as a potential treatment for chronic myeloid leukemia.
    Zaree Mahmodabady A; Javadi HR; Kamali M; Najafi A; Hojati Z
    Iran Biomed J; 2010; 14(1-2):1-8. PubMed ID: 20683492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of specific siRNA targeting at bcr-abl fusion gene and its combination with p27 gene clone on chronic myeloid leukemia cell line K562].
    Wang W; DU Y; Lin GQ; Li NN; Sun BZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):606-11. PubMed ID: 20561411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia.
    Zhu XS; Lin ZY; Du J; Cao GX; Liu G
    Asian Pac J Cancer Prev; 2014; 15(12):4773-80. PubMed ID: 24998540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia.
    Koldehoff M; Elmaagacli AH
    Methods Mol Biol; 2009; 487():451-66. PubMed ID: 19301661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
    Sengupta A; Banerjee D; Chandra S; Banerjee S
    J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of lipid substitution on assembly and delivery of siRNA by cationic polymers.
    Aliabadi HM; Landry B; Bahadur RK; Neamnark A; Suwantong O; Uludağ H
    Macromol Biosci; 2011 May; 11(5):662-72. PubMed ID: 21322108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
    Freire JM; Rego de Figueiredo I; Valle J; Veiga AS; Andreu D; Enguita FJ; Castanho MA
    J Control Release; 2017 Jan; 245():127-136. PubMed ID: 27890856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
    Jyotsana N; Sharma A; Chaturvedi A; Budida R; Scherr M; Kuchenbauer F; Lindner R; Noyan F; Sühs KW; Stangel M; Grote-Koska D; Brand K; Vornlocher HP; Eder M; Thol F; Ganser A; Humphries RK; Ramsay E; Cullis P; Heuser M
    Ann Hematol; 2019 Aug; 98(8):1905-1918. PubMed ID: 31104089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.